Solid Biosciences (SLDB) Other Non Operating Income (2017 - 2026)
Quarterly results put Other Non Operating Income at $157000.0 for Q1 2026, down 16.49% from a year ago — trailing twelve months through Mar 2026 was $793000.0 (down 5.26% YoY), and the annual figure for FY2025 was $824000.0, up 26.38%.
Solid Biosciences has reported Other Non Operating Income over the past 10 years, most recently at $157000.0 for Q1 2026.
- Other Non Operating Income reached $157000.0 in Q1 2026 per SLDB's latest filing, down from $219000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $282000.0 in Q1 2023 and bottomed at -$355000.0 in Q4 2022.
- Median Other Non Operating Income over the past 5 years was $207000.0 (2025), compared with a mean of $138058.8.
- The largest annual shift saw Other Non Operating Income crashed 200.0% in 2022 before it skyrocketed 8933.33% in 2023.
- Over 5 years, Other Non Operating Income stood at -$355000.0 in 2022, then skyrocketed by 176.06% to $270000.0 in 2023, then dropped by 26.3% to $199000.0 in 2024, then rose by 10.05% to $219000.0 in 2025, then fell by 28.31% to $157000.0 in 2026.
- Business Quant data shows Other Non Operating Income for SLDB at $157000.0 in Q1 2026, $219000.0 in Q4 2025, and $210000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 157,000.00 |
| Dec 31, 2025 | 219,000.00 |
| Sep 30, 2025 | 210,000.00 |
| Jun 30, 2025 | 207,000.00 |
| Mar 31, 2025 | 188,000.00 |
| Dec 31, 2024 | 199,000.00 |
| Sep 30, 2024 | 211,000.00 |
| Jun 30, 2024 | 239,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Dec 31, 2023 | 270,000.00 |
| Sep 30, 2023 | 278,000.00 |
| Jun 30, 2023 | 265,000.00 |
| Mar 31, 2023 | 282,000.00 |
| Dec 31, 2022 | -355,000.00 |
| Sep 30, 2022 | -13,000.00 |
| Jun 30, 2022 | -3,000.00 |
| Mar 31, 2022 | -10,000.00 |
| Jun 30, 2021 | 3,000.00 |
| Mar 31, 2020 | 1,000.00 |
| Dec 31, 2019 | 170,000.00 |
| Sep 30, 2019 | 56,000.00 |
| Jun 30, 2019 | 77,000.00 |
| Mar 31, 2019 | 212,000.00 |
| Dec 31, 2018 | 83,000.00 |
| Sep 30, 2018 | 38,000.00 |
| Jun 30, 2018 | 118,000.00 |
| Mar 31, 2018 | 31,000.00 |
| Dec 31, 2017 | 93,000.00 |
| Sep 30, 2017 | 228,000.00 |
| Jun 30, 2017 | 504,000.00 |
| Mar 31, 2017 | 176,000.00 |